Simulations Plus Inc
NASDAQ:SLP
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Simulations Plus Inc
Additional Paid In Capital
Simulations Plus Inc
Additional Paid In Capital Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Additional Paid In Capital | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Simulations Plus Inc
NASDAQ:SLP
|
Additional Paid In Capital
$163.2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
32%
|
|
|
Veeva Systems Inc
NYSE:VEEV
|
Additional Paid In Capital
$2.8B
|
CAGR 3-Years
23%
|
CAGR 5-Years
24%
|
CAGR 10-Years
23%
|
|
|
Inspire Medical Systems Inc
NYSE:INSP
|
Additional Paid In Capital
$927.2m
|
CAGR 3-Years
4%
|
CAGR 5-Years
15%
|
CAGR 10-Years
N/A
|
|
|
Doximity Inc
NYSE:DOCS
|
Additional Paid In Capital
$894.2m
|
CAGR 3-Years
8%
|
CAGR 5-Years
127%
|
CAGR 10-Years
N/A
|
|
|
Omnicell Inc
NASDAQ:OMCL
|
Additional Paid In Capital
$1.2B
|
CAGR 3-Years
5%
|
CAGR 5-Years
6%
|
CAGR 10-Years
10%
|
|
|
W
|
Waystar Holding Corp
NASDAQ:WAY
|
Additional Paid In Capital
$4B
|
CAGR 3-Years
21%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Simulations Plus Inc
Glance View
Simulations Plus, Inc. provides modeling and simulation software and consulting services supporting drug discovery, development research and regulatory submissions. The company is headquartered in Lancaster, California and currently employs 135 full-time employees. The company provides prediction of properties of molecules utilizing artificial-intelligence- and machine-learning-based technology. The company also provides consulting services ranging from early drug discovery through preclinical and clinical trial development to regulatory submissions in support of product approval. The company offers 11 software products for pharmaceutical research and development, which includes GastroPlus, DDDPlus, MembranePlus, DILIsym, NAFLDsym, ADMET Predictor, MedChem Designer, MedChem Studio, PKPlus, KIWI and Monolix Suite of products through Lixoft. Its software and consulting services are provided to pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies and to academic and regulatory agencies worldwide for use in the conduct of industry-based research. Cognigen Corporation, DILIsym Services, Inc. and Lixoft are its subsidiaries.
See Also
What is Simulations Plus Inc's Additional Paid In Capital?
Additional Paid In Capital
163.2m
USD
Based on the financial report for Feb 28, 2026, Simulations Plus Inc's Additional Paid In Capital amounts to 163.2m USD.
What is Simulations Plus Inc's Additional Paid In Capital growth rate?
Additional Paid In Capital CAGR 10Y
32%